Press release from Companies
Published: 2024-12-13 14:44:46
Peter Egelberg, founder and Board member of Phase Holographic Imaging PHI AB ("PHI" or the "Company") has notified the Company that he, together with closely related parties, follows Altium SA’s lead by subscribing for shares in the Company’s ongoing fully secured rights issue. The subscription amounts to approximately 300 TSEK.
Peter Egelberg, founding Board Member of PHI, comments
"The lack of robust automation has long limited the use of microscopy in manufacturing environments. Since resigning as CEO, I have gone back to my roots in software development, AI, physics and mathematics to solve this long-standing problem. Together with the PHI development team, I have now spent nearly two years improving HoloMonitor’s QPI technology. The results have convinced me that PHI will soon be able to offer unprecedented automation of image-based cell analysis for applications in medical research, biomanufacturing and clinical regenerative medicine, which is bound to attract attention in the life science industry."
Advisors
Navia Corporate Finance AB is the financial advisor and Sole Bookrunner in connection with the rights issue. HWF Advokater AB is the legal advisor. Nordic Issuing AB is the issuing agent.
For more information about the rights issue, please contact:
Navia Corporate Finance AB
E-mail: info@naviacf.se
Website: www.naviacorporatefinance.com
For additional information, please contact:
Anders Månsson
E-mail: ir@phiab.com
Web: www.phiab.com – Live cell imaging & analysis
About PHI
Phase Holographic Imaging (PHI) is a medical technology company that develops and markets its non-invasive time-lapse imaging instruments for long-term quantitative analysis of living cells. The foundation of PHI’s current commercial HoloMonitor® products is Quantitative Phase Imaging (QPI) technology — an innovative approach to cell quality evaluation. QPI offers detailed analysis of cell characteristics without harming the cells, avoiding the limitations of traditional measurement methods. PHI is actively focusing on business development to expand from pre-clinical research to the clinical market and the emerging regenerative medicine field. PHI envisions transforming live cell analysis and establishing QPI as a standard for cell quality control, making future cell therapies safe, affordable, and accessible for patients. PHI is based in Lund, Sweden, Boston, MA and Winston-Salem, NC.